Treatment of squamous cell esophageal cancer with topotecan: an Eastern Cooperative Oncology Group Study (E2293)

Seventeen patients with enhanced measurable squamous cell carcinoma of the esophagus were treated with topotecan 1.5 mg/m2 daily for 5 days repeated every 21 days. Toxicity was severe, with 1 death from myelotoxicity and 10 patients with life-threatening myelotoxicity. Severe gastrointestinal toxici...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of clinical oncology Vol. 23; no. 1; p. 45
Main Authors Asbury, R F, Lipsitz, S, Graham, D, Falkson, C I, Baez, L, Benson, 3rd, A B
Format Journal Article
LanguageEnglish
Published United States 01.02.2000
Subjects
Antineoplastic Agents - therapeutic use
Carcinoma, Squamous Cell - drug therapy
Esophageal Neoplasms - drug therapy
Humans
Topotecan - therapeutic use
Online AccessGet more information

Cover

More Information
Summary:Seventeen patients with enhanced measurable squamous cell carcinoma of the esophagus were treated with topotecan 1.5 mg/m2 daily for 5 days repeated every 21 days. Toxicity was severe, with 1 death from myelotoxicity and 10 patients with life-threatening myelotoxicity. Severe gastrointestinal toxicity consisting of vomiting was also seen in three patients. No response was seen in any of the patients in the study. Topotecan given in this manner has no activity in squamous cell carcinoma of the esophagus.
ISSN:0277-3732
DOI:10.1097/00000421-200002000-00013